Synbiotics Interventions for Managing Cirrhosis and Its Complications

• Status: Completed
• Trial end date: 2022-10-24
• Target enrollment: 0
• Participant gender: All

Summary

Background Liver cirrhosis is commonly accompanied by intestinal dysbiosis and metabolic defects. Many clinical trials have shown microbiota-targeting strategies represent promising interventions for managing cirrhosis and its complications. However, the influences of the intestinal metagenomes and metabolic profiles of patients have not been fully elucidated.

Methods administered lactulose, Clostridium butyricum, and Bifidobacterium longum infantis as a synbiotic and used shotgun metagenomics and non-targeted metabolomics to characterize the results.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: First Affiliated Hospital of Zhejiang University
• Treatments: Entecavir; Lactulose; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• ① Hepatitis B cirrhosis was diagnosed by clinical biochemistry and imaging.

• CTP rating is a-b.

• There was a previous liver cirrhosis complication, including ascites, spontaneous peritonitis, massive gastrointestinal bleeding, liver coma, etc.

• Over 18 years old. ⑤ Under 90 years old.

• The patient or family member signs the informed consent form.

Exclusion Criteria:

• ① The CTP of liver cirrhosis was evaluated as grade C.

• Other types of cirrhosis such as primary biliary cirrhosis.

• Pregnancy status. ④ Have a history of diabetes, renal insufficiency, gastrointestinal surgery, etc.

• Antibiotics, PPI preparations and microecological preparations (including yogurt) have been used in the past 8 weeks.

• Have a history of narcotic drug abuse, drug abuse, or mental illness. ⑦ Patients and their families do not agree to sign the informed consent form. ⑧ Under 18 years old or over 90 years old.